Cidara Therapeutics, Inc. (CDTX) Dividend History

Company News

• Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

  Cidara Therapeutics, a biotechnology company, announced that it has granted a new employee, Timothy Alefantis, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock. The awards are subject to the employee's continuous service and the terms of the company's Inducement Incentive Plan.

  GlobeNewswire Inc.
• Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

  Cidara Therapeutics, a biotechnology company, announced that its President and CEO will participate in the Evercore 7th Annual HealthCONx Conference. The company's lead drug-Fc conjugate candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza, and the company also has a candidate, CBO421, intended to target CD73 in solid tumors.

  GlobeNewswire Inc.
• Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

  Cidara Therapeutics, a biotechnology company, announced that it granted a new employee, Dipesh Bhatt, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock. The company also corrected a previous press release regarding the number of shares granted to Jim Beitel.

  GlobeNewswire Inc.
• Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

  Cidara Therapeutics announced two presentations at the OPTIONS XII for the Control of Influenza conference, highlighting safety and pharmacokinetic data from clinical studies of their influenza drug-Fc conjugate candidate, CD388.

  GlobeNewswire Inc.
• Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

  Cidara Therapeutics has dosed the first subjects in a Phase 2b trial to evaluate the efficacy and safety of its drug candidate CD388 for the prevention of seasonal influenza. CD388 is designed to provide universal protection against all known strains of seasonal and pandemic influenza.

  GlobeNewswire Inc.